optioncare_ig-icon

Immunoglobulin

Home Infusion Plus

Option Care offers industry-leading expertise, access, and support in immunoglobulin (IG) infusion therapy. Each year, we provide more than 80,000 IG home infusions across the country. We are contracted with more than 800 health plans and have a >96% success rate in overturning benefit denials.1

Setting the standard in IG therapy

Dedicated IG Centers of Excellence

Option Care clinically manages all IG patients through our focused, centralized Centers of Excellence, while our nationwide team of 1800+ clinicians deliver care locally.

Powered by PartnerPoint Clinical Management®

Best-practice IG patient management technology helps coordinate care and demonstrates improved outcomes.

Better long-term outcomes

Best patient outcomes reflect optimized regimens and high adherence, resulting in lower financial burden.

Watch how IG Home Infusion Plus is changing lives

Play the video to hear what patients, clinicians, and leaders have to say about IG Home Infusion Plus.
(用中文观看 / Véalo en español)

All immunoglobulin therapy patients are managed by our IG Centers of Excellence

Option Care centrally manages all IG patients with PartnerPoint, while providing local hands-on care for nearly all patients across the United States.2

Option Care improves the patient experience across the continuum of care, starting before the first dose

Time-saving intake coordination
All immunoglobulin therapy patients who are referred to Option Care begin their intake process through one of our IG Centers of Excellence, where our intake specialists verify insurance eligibility and secure health plan authorization for patients. Our insurance and reimbursement assistance saves prescribers time so that patients can start treatment sooner.

Individualized care plans
Option Care provides personalized medical care that is anchored by a dedicated IG nurse and IG pharmacist. Every patient receives a disease-specific, customized care plan that is focused solely on meeting the needs of the patient and his or her care team. Each home infusion is administered by a trained IG nurse, and treatments can be administered in the most convenient setting—at home, in a physician’s or healthcare provider’s office, or in a nearby infusion suite.

Clinical monitoring and reporting
Option Care conducts evaluations and provides patient management for all IG patients through PartnerPoint Clinical Management®. PartnerPoint helps clinicians demonstrate response to therapy and identify the therapeutic regimens that optimize patient outcomes. Ongoing evaluations keep prescribing physicians informed and alert to additional needs for patient support beyond IG therapy, like psychosocial or nutritional support.

Long-term support and education
Option Care is built on long-term nursing relationships, ensuring that patients receive personalized and expert nursing care. In addition, our regional IG Centers of Excellence provide ongoing patient management, comprehensive patient and caregiver educational resources, and 24/7 patient support.

Anyone can dispense IG therapy but it is the clinical expertise, oversight and patient support that makes a difference.  These are central to quality patient care at Option Care.”

-Andrea Roberts, National Clinical Director

PartnerPoint Clinical Management® helps improve outcomes from the start of therapy

PartnerPoint is a patient-reported outcomes measure (PROM) administered to IG patients during intake and at each home visit. The nurse (or pharmacist) conducts a clinical interview with patients and collects the data at the site of care. Option Care makes the clinical management data reportable and accessible to prescribing physicians, thereby increasing their ability to manage adverse drug reactions, monitor patient quality of life, optimize dosing, and demonstrate response to therapy.

PartnerPoint is a best-practice IG patient management program that optimizes therapeutic regimens and patient outcomes by increasing communication across all members of a patient’s care team and providing more opportunities for critical clinical interventions. PartnerPoint provides disease-specific patient outcomes data for more than 10 conditions, including chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and primary immunodeficiency disease (PID).

Reliably assess patients in the home setting
The results of our in-home evaluations are consistent with those performed by physicians.

Our goal in developing PartnerPoint was to create a clinically reliable way to measure patient outcomes in a remote setting, and report those results back to all members of the patient care team.”

-Gretchen Ayer, Director of Business Development

Customized treatment for complex neurologic and immunologic conditions

Option Care has access to all available intravenous and subcutaneous immunoglobulin therapies for customized, uninterrupted treatment. IG therapy is used to treat multiple conditions, including the following:

  • Autoimmune encephalopathy
  • Chronic granulomatous disease
  • Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Common variable immunodeficiency
  • Dermatomyositis
  • Guillain-Barré syndrome (GBS)
  • Hyper IgM syndrome
  • Idiopathic thrombocytopenic purpura (ITP)
  • Lambert-Eaton syndrome
  • Mononeuritis multiplex
  • Multifocal motor neuropathy (MMN)
  • Multiple sclerosis (MS)
  • Myasthenia Gravis (MG)
  • Neonatal alloimmune thrombocytopenia (NAIT)
  • Pemphigoid
  • Pemphigus
  • Peripheral neuropathy
  • Polymyositis
  • Pre-and post-transplant
  • Selective IgA deficiency
  • Selective immunoglobulin deficiencies
  • Severe combined immunodeficiency
  • Stiff person syndrome (SPS)
  • Wiskott-Aldrich syndrome
  • X-linked agammaglobulinemia

References:
1. Data on file, Option Care. 2. Option Care coverage area data. STI: PopStats, Austin, TX. Calculated 04/28/14. 3. Silvestri N, Ladha S, Mozaffar T, Ayer G, Betts LM. Patient-reported outcomes—an emerging cornerstone of effective intravenous immunoglobulin therapy. US Neurology. 2015;11(1):40-46.